Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2005-10-11
2005-10-11
Chen, Shin-Lin (Department: 1632)
Chemistry: molecular biology and microbiology
Vector, per se
C435S455000, C424S093200, C424S093210, C536S023500, C536S024100
Reexamination Certificate
active
06953687
ABSTRACT:
Cell transformation vectors for inhibiting HIV and tumor growth are provided. Optionally, the vectors encode RNAses such as EDN. Cells transduced by the vectors and methods of transforming cells (in vitro and in vivo) using the vectors are also provided.
REFERENCES:
patent: 0334301 (1989-09-01), None
patent: 0334301 (1989-09-01), None
Poeschia et al.,Development of HIV vectors for anti-HIV gene therapy, Oct. 1996, PROC. NATL. ACAD. SCI., vol. 93 pp. 11395-11399.
Vile et al, Retroviruses as vectors, 1995, British Medical Bulletin, vol. 51 No. 1 pp. 12-30.
Verma et al., Gene therapy-promises, problems and prospects, Spt. 1997, Nature, vol. 389 pp. 239-242.
Crystal, Transfer of genes to humans: Early lessons and obstacles to success, Oct. 1995, Science, vol. 270 pp. 404-410.
Ding et al., A single amino acid determines the immunostimulatory activity of interleukin Jan. 10, 2000, J. Esp. Med., vol. 191 No. 2, pp. 213-223.
Deonarain, Ligand-targeted receptor-mediated vectors for gene therapy, 1998, Exp. Opin.Ther. Patent, vol. 8 No. 1 pp. 53-69.
Eck et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 1996, McGraw-Hill, New York, p. 77-101.
Gorecki, D., 2001, Expert opin. Emerging Drugs, vol. 6, No. 2, p. 187-198.
Akkina, et al. “High-Efficiency Gene Transfer into CD34+Cells with a Human Immunodeficiency Virus Type 1-Based Retroviral Vector Pseudotyped with Vesicular Stomatitis Virus Envelope Glycoprotein G”J. of VirologyApr. 1996 vol. 70 (4) pp. 2581-2585.
Bahner, et al. “Comparison of trans-Dominant Inhibitory Mutant Human Immunodeficency Virus Type 1 Genes Expressed by Retroviral Vectors in Human T Lymphocytes”J. of VirologyJun. 1993 vol. 67 (6) pp. 3199-3207.
Brenner, Malcom, K. “Gene Transfer into Human Hematopoietic Progenitor Cells: A Review of Current Clinical Protocols”J. of Hematotherapy(1993) vol. 2 pp. 7-17.
Chang, et al. “Regulation by HIV Rev Depends upon Recognition of Splice Sites”CellDec. 1989 vol. 59 pp. 789-795.
D'Agostino, et al. “The Rev Protein of Human Immodeficiency Virus Type 1 Promotes Polysomal Association and Translation of gag/pol and vpu/env mRNAs”Molecular and Cellular BiologyMar. 1992 vol. 12 (3) 1375-1386.
Felber, et al. “Rev Protein of Human Immunodeficiency Virus Type 1 Affects the Stability and Transport of the Viral mRNA”Proc. Natl. Acad. Sci.Mar. 1989 vol. 86 pp. 1495-1499.
Feinberg, et al. “Intracellular Immunization: Trans-Dominant Mutants of HIV Gene Products as Tools for the Study and Interruption of Viral Replication”AIDS Research and Human Retroviruses(1992) vol. 8 (6) pp. 1013-1022.
Ghattas, et al. “The Encephalomyocarditis Virus Internal Ribosome Entry Allows Efficient Coexpression of Two Genes from a Recomb Provirus in Cultured Cells and in Embryos”Molecular and Cellular BiologyDec. 1991 vol. 11 pp. 5848-5859.
Hsieh, et al. “Improved Gene Expression by a Modified Bicistronic Retroviral Vector”Biochemical and Biophysical Research CommunicationSep. 1995 vol. 214 (3) pp. 910-917.
Itoh, et al. “HTLV-1 rex and HIV-1 rev Act Through Similar Mechanisms to Relieve Suppression of Unspliced RNA Expression”Oncogene(1989) vol. 4 pp. 1275-1279.
Levine, et al. “Efficient Gene Expression in Mammalian Cells from a Dicistronic Transcriptional Unit in an Improved Retroviral Vector”Gene(1991) vol. 108 pp. 167-174.
Moore, Malcolm, A.S. “Ex Vivo Expansion and Gene Therapy Using Cord Blood CD34+Cells”Journal of Hemotherapy(1993) vol. 2 pp. 221-224.
Nable, et al. “A Molecular Genetic Intervention for AIDS—Effects of a Transdominant Negative for of Rev”Human Gene Therapy(1994) vol. 5 pp. 79-80.
Naldini, et al. “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector”ScienceApr. 1996 vol. 272 ppl 263-267.
Poeschla, et al. “Development of HIV Vectors for Anti-HIV Gene Therapy”Proc. Natl. Acad. Sci.Oct. 1996 vol. 93 pp. 11395-11399.
Tan, et al. “Inhibitory Activity of the Equine Infectious Anemia Virus Major 5′ Splice Site in the Absence of Rev”J. of VirologyJun. 1996 vol. 70 (6) pp. 3645-3658.
Thierry, et al. “Systemic Gene Therapy: Biodistribution and Long-term Expression of a Transgene in Mice”Proc, Natl. Acad. Sci.Oct. 1995 vol. 92 pp. 9742-9746.
Trono, et al. “HIV-1 Gag Mutants Can Dominantly Interfere with the Replication of the Wild-Type Virus”CellOct. 1989 vol. 59 pp. 113-120.
Venkatesh, et al. “Selective Induction of Toxicity to Human Cells Expressing Human Immunodefiency Virus Type 1 Tat by a Conditionally Cytotoxic Adenovirus Vector”Proc. Natl. Acad. Sci.Nov. 1990 vol. 87 pp. 8746-8750.
Youle, et al. “RNase Inhibition of Human Immunodeficiency Virus Infections of H9 Cells”Proc. Natl. Acad. Sci.Jun. 1994 vol. 91 pp. 6012-6016.
Yu, et al. “Progress Towards Gene Therapy for HIV Infection”Gene Therapy(1994) vol. 1 pp. 13-26.
Zenke, et al. “Receptor-mediated Endocytosis of Transferrin-polycation Conjugates: An Efficient Way to Introduce DNA into Hematopietic Cells”Proc. Natl. Acad. Sci.May 1990 vol. 87 pp. 3655-3659.
Cara Andrea
Gusella Gabriele Luca
Newton Dianne
Rybak Susanna
Chen Shin-Lin
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Vectors for delivering viral and oncogenic inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vectors for delivering viral and oncogenic inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vectors for delivering viral and oncogenic inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3481752